ConductScience.org, home

Paper34412058

Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders.

Hill SF and 1 other. Dev Neurosci, 2021. Cited by 69 papers, by iCite.

Cite this record

ConductScience Library. Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders. Papers, record 34412058. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34412058

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders.
PubMed
Journal
Dev Neurosci
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Review
PubMed
Citations, by iCite
69
iCite
Relative citation ratio, by iCite
3.95
iCite
Revised in PubMed
2023-11-07
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hill SFSophie F
2Meisler MHMiriam H

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Muscular Atrophy, SpinalMajor topic
Neurodevelopmental DisordersMajor topic
Animals
Disease Models, Animal
Humans
Mice
NAV1.1 Voltage-Gated Sodium Channel
Oligonucleotides, Antisense
RNA Splicing

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 NS034509NINDS NIH HHSUnited StatesR01NS034509PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131506303Nusinersen for Type 1 Spinal Muscular Atrophy: A Father's Perspective.Pediatrics2019https://conductscience.org/library/papers/31506303PubMed
217537961Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation.J Neurosci2007https://conductscience.org/library/papers/17537961PubMed
38390996Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression.J Biol Chem1993https://conductscience.org/library/papers/8390996PubMed
433531663Sodium channelopathies in neurodevelopmental disorders.Nat Rev Neurosci2021https://conductscience.org/library/papers/33531663PubMed
524784568Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates.J Pharmacol Exp Ther2014https://conductscience.org/library/papers/24784568PubMed
625568300The phenotypic spectrum of SCN8A encephalopathy.Neurology2015https://conductscience.org/library/papers/25568300PubMed
733307321Children and young adults with spinal muscular atrophy treated with nusinersen.Eur J Paediatr Neurol2021https://conductscience.org/library/papers/33307321PubMed
828192393Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy.Nat Neurosci2017https://conductscience.org/library/papers/28192393PubMed
920624852Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.Genes Dev2010https://conductscience.org/library/papers/20624852PubMed
1031943325Scn8a Antisense Oligonucleotide Is Protective in Mouse Models of SCN8A Encephalopathy and Dravet Syndrome.Ann Neurol2020https://conductscience.org/library/papers/31943325PubMed
119259265The survival motor neuron protein in spinal muscular atrophy.Hum Mol Genet1997https://conductscience.org/library/papers/9259265PubMed
129077498A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients.J Neurol Sci1997https://conductscience.org/library/papers/9077498PubMed
1331036929Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.Nat Biotechnol2019https://conductscience.org/library/papers/31036929PubMed
1428244990The chemical evolution of oligonucleotide therapies of clinical utility.Nat Biotechnol2017https://conductscience.org/library/papers/28244990PubMed
159880552Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression.J Biol Chem1999https://conductscience.org/library/papers/9880552PubMed
1621971427Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.Mol Ther2011https://conductscience.org/library/papers/21971427PubMed
1727939059Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.Lancet2016https://conductscience.org/library/papers/27939059PubMed
187813012Identification and characterization of a spinal muscular atrophy-determining gene.Cell1995https://conductscience.org/library/papers/7813012PubMed
1929091557Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.N Engl J Med2017https://conductscience.org/library/papers/29091557PubMed
2021482919Spinal muscular atrophy: a timely review.Arch Neurol2011https://conductscience.org/library/papers/21482919PubMed

See all 28 referencesDownload CSV of references

Cited by57

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.

PMIDTitleJournalYearIn PapersSource
42742464Neural Stem Cell-Derived Extracellular Vesicles Improve CNS Delivery and Therapeutic Efficacy of Antisense Oligonucleotide in Amyotrophic Lateral Sclerosis.J Extracell Vesicles2026https://conductscience.org/library/papers/42742464PubMed
42737622RNA-Based Therapeutics in Genetic Neurodevelopmental Disorders: Bridging Molecular Genetics and Precision Medicine.Int J Mol Sci2026https://conductscience.org/library/papers/42737622PubMed
42441133HNF1B-related disease: developmental origins, molecular mechanisms, and multisystem clinical challenges.Clin Kidney J2026https://conductscience.org/library/papers/42441133PubMed
42095821[Spinal muscular atrophy: Clinical and genetic aspects, and therapeutic alternatives].Rev Med Inst Mex Seguro Soc2026https://conductscience.org/library/papers/42095821PubMed
42071079Bridging development and disease: the potential of LncRNAs as biomarkers and therapeutics in pediatric neurological disorders.Pediatr Res2026https://conductscience.org/library/papers/42071079PubMed
41678398Alternative splicing-triggered mRNA decay informs splice-switching targets for neurodevelopmental disorders.J Clin Invest2026https://conductscience.org/library/papers/41678398PubMed
41515912From Symptomatic Therapies to Disease-Modifying Approaches for Neuronal Sodium Channel Disorders.Int J Mol Sci2025https://conductscience.org/library/papers/41515912PubMed
41509361Rescuing Neurodevelopmental Deficits in AMPA Receptor Gain-of-Function Mutant.bioRxiv2025https://conductscience.org/library/papers/41509361PubMed
41465141Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders.Genes (Basel)2025https://conductscience.org/library/papers/41465141PubMed
41323796SCAD: A modular platform for efficient delivery of duplex RNA to the CNS and beyond.Mol Ther Nucleic Acids2025https://conductscience.org/library/papers/41323796PubMed
41153385RNA-Targeting Techniques: A Comparative Analysis of Modern Approaches for RNA Manipulation in Cancer Research and Therapeutics.Genes (Basel)2025https://conductscience.org/library/papers/41153385PubMed
40808385Voltage-gated sodium channels in the nervous system: Molecular physiology to therapeutic interventions.Neural Regen Res2026https://conductscience.org/library/papers/40808385PubMed
40534528RNA Therapeutics: Focus on Antisense Oligonucleotides in the Nervous System.Biomol Ther (Seoul)2025https://conductscience.org/library/papers/40534528PubMed
40523177Single Antisense Oligonucleotides Correct Diverse Splicing Mutations in Hotspot Exons.Proc Natl Acad Sci U S A2025https://conductscience.org/library/papers/40523177PubMed
40400017Systematic analysis of genetic and phenotypic characteristics reveals antisense oligonucleotide therapy potential for one-third of neurodevelopmental disorders.Genome Med2025https://conductscience.org/library/papers/40400017PubMed
40295879Interictal network dysfunction and cognitive impairment in epilepsy.Nat Rev Neurosci2025https://conductscience.org/library/papers/40295879PubMed
40217359Genetic mechanisms in generalized epilepsies.Acta Epileptol2023https://conductscience.org/library/papers/40217359PubMed
40160416Elucidating neuroepigenetic mechanisms to inform targeted therapeutics for brain disorders.iScience2025https://conductscience.org/library/papers/40160416PubMed
39991982Natural History of NAA15 -Related Neurodevelopmental Disorder Through Adolescence.Am J Med Genet A2025https://conductscience.org/library/papers/39991982PubMed
39989508Patient leadership and partnerships accelerate therapies for SCN8A and other developmental and epileptic encephalopathies.Ther Adv Rare Dis2025https://conductscience.org/library/papers/39989508PubMed

See all 57 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
MFSD8256471PubTator's text mininghttps://conductscience.org/library/genes/256471NCBI Gene
RNASEH1246243PubTator's text mininghttps://conductscience.org/library/genes/246243NCBI Gene
SCN1A6323PubTator's text mininghttps://conductscience.org/library/genes/6323NCBI Gene
SCN8A6334PubTator's text mininghttps://conductscience.org/library/genes/6334NCBI Gene
SMN16606PubTator's text mininghttps://conductscience.org/library/genes/6606NCBI Gene
SMN26607PubTator's text mininghttps://conductscience.org/library/genes/6607NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34412058

GET https://conductscience.org/api/papers/v1/34412058/references?page=2